Healthcare

ResMed is a Buy based on five tailwinds: Goldman Sachs

Thu 03 Feb 22, 6:56pm (AEST)
image

Stocks in article

rmd
MktCap:
-

Share article

Key Points

  • Goldman’s expects pressures to progressively ease through the coming quarters
  • Goldman's believes near-term challenges mask five key longer-term tailwinds
  • Consensus rating is Buy

Resmed’s (ASX: RMB) second quarter FY22 update, released 27 January, did little to alleviate Goldman Sachs’ concerns that supply shortages will continue to hamper near-term upside. But over the long-term, the broker believes there are more tailwinds to add to the recent recall saga responsible for driving recent earnings higher.

Resmed’s second quarter FY22 update revealed a 13% jump in revenue for the three months to December.

Much of the group’s recent revenue can be attributed to increased demand for its care devices, courtesy of a recent product recall by Royal Philips (AMS: PHIA). ResMed also benefitted from continuing tailwinds from covid-related demand for its respiratory devices, and mask products.

But given that the recall tailwind of $45-55m in the second quarter represented a sharp sequential slowdown from $80-90m in first quarter, Goldman’s is now forecasting the FY22 benefit at $285m, below the guided range of $300-350m.

Unsurprisingly, given that growth didn’t meet analyst expectations the share price has been treading water ever since.

But the share price was up 1.22% at the close today.

Supply issues to progressively ease

But over the slightly longer-term, the broker sees the dual New York Stock Exchange and ASX-listed medical devices giant as a frontrunner within an attractive market with long-term, realisable penetration upside.

While ongoing supply/distribution headwinds add cost and complexity to near-term performance, Goldman’s expects these pressures to progressively ease through the coming quarters.

In short, the broker argues that recent share price softness -22% versus the ASX200 since mid-September – has more to do with macro/sector-wide factors than company-related specifics.

What the broker is alluding to is the attractiveness of the current price, relative to the drivers that are now propelling the stock forward.

Five key drivers

Despite lowering the 12-month target price to $35.80, the broker has upgraded ResMed to a Buy rating having concluded that near-term challenges are masking five key longer-term tailwinds, these include:

  • High profitability, (with a 34% earning margin), strongly cash-generative a robust balance sheet which is 0.5x geared.

  • A stronger competitive position than across most of its history.

  • Industry-wide price tailwinds and is also successfully sharing its own cost growth with customers.

  • Relative to growth, ResMed is the cheapest large healthcare manufacturer on the ASX, with 11%-plus FY22-25 earnings compound annual growth rate (CAGR).

  • The stock has materially de-rated relative to the market since mid-Sept, affording the best entry point since announcement of the competitor recall.

Risks

While ResMed uses a different type of foam across its CPAP devices versus PHIA, the broker concedes that regulatory scrutiny from the PHIA recall could broaden out to other manufacturers.

While such a product recall would materially challenge the business and drive downward revisions to Goldman’s earnings forecasts, the broker believes this scenario remains unlikely.

Similarly, while Goldman’s expects the eventual recovery in new diagnoses, the broker admits that a resurgence of covid cases globally could potentially delay the recovery trajectory in the near term.

image

 

While materially lower, ResMed still managed to outperform the broader healthcare sector over the last 12 months.

What other brokers think

Based on the six brokers that cover ResMed (as reported on by FN Arena) the target price represents a 15.2% upside to the current price of $33.20.

Five of the six stocks have a Buy rating (or equivalent).

  • Morgans notes the second quarter result was softer than market expectations and lowers the target price to $40.46 from $40.80 (01/02/22).

  • Macquarie has a bullish outlook on medium-term growth and is impressed by the group’s strong balance sheet. Target price increases $38.50 from $38.40 (31/01/22).

  • Despite impacts of supply chain disruptions and elevated freight and manufacturing costs on gross margins, Citi still expects ResMed to deliver notable growth in FY22. In light of the recent share price weakness the broker's rating is upgraded to Buy, and the target price is lowered to $38.00 from $38.50 (31/01/22).

 

Written By

Mark Story

Editor

Mark is an investigative financial journalist and editor who started his career working for Marathon Oil in London. He has a degree in politics/economics and a diploma in journalism. Mark has worked on 70-plus newspapers and financial publications across Australia, NZ, the US, and Asia including: The Australian Financial Review, Money Magazine, Australian Property Investor and Finance Asia. Mark is passionate about improving the financial literacy of all Australians through the highest quality content. Email Mark at [email protected].

Get the latest news and media direct to your inbox

Sign up FREE